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Running title: ALA importance in combating stroke 
 
 
Highlights 
 
ALA was evaluated as a nutraceutical in rodent model of ischemic stroke. 
ALA supplementation by modification of the daily diet prevents mortality and cerebral 
damage. 
ALA stimulates neuronal protection, neuroplasticity, and brain artery vasodilation. 
ALA stimulates brain preconditioning mechanisms. 
We propose the novel concept of brain preconditioning by nutraceuticals against stroke. 
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Abbreviations  
ALA: Alpha-Linolenic Acid 
ANSES: Agence Nationale pour la Sécurité et la Santé 
BDNF: Brain Derived Neurotrophic Factor 
CVD: CardioVascular diseases 
DHA: DocosaHexaenoic Acid 
EPA: EicosaPentaenoic Acid 
LA: linolenic acid 
LC omega-3: long-chain omega-3 (eg, mainly EPA and DHA) 
 MCAO: middle cerebral artery occlusion 
PUFA: polyunsaturated fatty acids  
SNAP-25: Synaptosomal-Associated Protein 25 
VAMP-2: Vesicle-Associated Membrane Protein 2 
VGLUT1: Vesicular Glutamate Transporter 1 
VGLUT2: Vesicular Glutamate Transporter 2 
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Abstract: 
 
 Stroke is a worldwide major cause of mortality and morbidity. Preclinical studies have 
identified over 1000 molecules with brain-protective properties. More than 200 clinical trials 
have evaluated neuroprotective candidates for ischemic stroke yet, to date almost all failed, 
leading to a re-analysis of treatment strategies against stroke. An emerging view is to seek 
combinatory therapy, or discovering molecules able to stimulate multiple protective and 
regenerative mechanisms. A pertinent experimental approach to identify such candidates is 
the study of brain preconditioning, which refers to how the brain protects itself against 
ischemia and others stress-inducing stimuli. The recent discovery that nutrients like alpha-
linolenic acid (ALA is an essential omega-3 polyunsaturated fatty acid required as part of our 
daily diet), may be an efficient brain preconditionner against stroke fosters the novel concept 
of brain preconditioning by nutraceuticals. 
  This review stresses the underestimated role of nutrition in preventing and combating 
stroke. Although there is a consensus that increased consumption of salt, fatty foods and 
alcoholic beverages may promote pathologies like hypertension, obesity and alcoholism - all 
of which are well known risk factors of stroke - few risk factors are attributed to a deficiency 
in an essential nutrient in the diet. The ALA deficiency observed in the Western modern diets 
may itself constitute a risk factor. 
 This review outlines how ALA supplementation by modification of the daily diet 
prevented mortality and cerebral damage in a rodent model of ischemic stroke. It also 
describes the pleiotropic ability of ALA to trigger responses that are multicellular, 
mechanistically diverse, resulting in neuronal protection, stimulation of neuroplasticity, and 
brain artery vasodilation. Overall, this review proposes a promising therapeutic opportunity 
by integrating a nutritional-based approach focusing on enriching the daily diet in ALA to 
prevent the devastating damage caused by stroke. 
 
Keywords: 
Ischemic stroke - brain preconditioning - neuroprotection - omega-3 polyunsaturated fatty 
acids – functional food - synaptogenesis - neurogenesis - nutraceutical - enriched diet  
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1. Stroke is a worldwide main cause of mortality and morbidity, lacking therapeutic 
options 
 
Stroke is a devastating disease in developed and 3
rd
 world countries, due to its high incidence, 
its brutal impact on the patient and its relatives, and the lack of therapeutic options. On 
average, someone has a stroke every 40 and 90 seconds in the United States and Europe, 
respectively [1, 2]. Annually, 15 million people worldwide suffer a stroke. The total number 
of stroke deaths is estimated at a half million people per year in European Union and is three 
time higher in the U.S. Of these, 30% die and another 30% are left permanently disabled, 
placing a tremendous burden on family and community. The estimated cost of stroke for 2010 
was $74 billion and €64 billion in the U.S and Europe, respectively [2, 3]. 
 
For the public, stroke is better known as brain attack, because it strikes in 85% of the cases by 
disrupting the blood flow to part of the brain due to occlusion of a blood vessel feeding the 
brain. Stroke is therefore a hypoxic-ischemic injury, whose pathophysiology involves 
glutamate, the major physiological excitatory neurotransmitter in the brain. The lack of 
oxygen and glucose causes a massive release of glutamate from neurons, and the 
overactivation (excitotoxicity) of ionotropic glutamate receptors, predominantly the N-
methyl-D-aspartate (NMDA) glutamate receptor subtype. This results in accumulation of 
intracellular calcium, which in turn triggers deleterious cascades including activation of lytic 
enzymes, mitochondrial dysfunction, oxidative stress and inflammation [4] in two regions that 
coexist within the infarct: the necrotic core and the ischemic penumbra, an area surrounding 
the core where neurons remain on the brink of survival or death for hours [5]. 
 
The progresses in understanding its complex interplay of multiple cellular and signaling 
pathways that alter the neurovascular unit integrity within differentially affected territories 
allowed identification in preclinical studies of neuroprotective targets or/and drugs blocking 
the neurotoxic ischemic cascade. Nevertheless, of those tested in clinical trials, all have failed, 
leaving patients and clinicians without any repertoire of therapeutic opportunities exerting 
direct protection of the neurons [6]. Consequently, the only approved therapeutic exerts its 
benefits through the restoration of the blood flow to the brain by blood clot disruption. It is 
performed by recombinant tissue plasminogen activator (tPA) treatment administered to 
approximately 5% of stroke patients. On the positive side, three definitive points are worth 
noting: 1) Efforts have been made over the past decades in high-income countries to control 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Page 5 of 21 
major risk factors like hypertension, diabetes, and high cholesterol, strides which have 
contributed to stroke mortality reduction. This success is associated with a global 
improvement in population health. It should be monitored cautiously as it probably represents 
the tip of the iceberg because stroke mortality represents, at the maximum, a third of the 
annual first-ever strokes; 2) The failure in translation from experimental models to clinical 
trials has lead to revisiting the research of strategies against stroke, resulting in a set of drug 
development criteria, collectively known as the Stroke Therapy Academic Industry 
Roundtable (STAIR) recommendations [7]; and 3) There is an acceleration in the study of 
unconventional therapies, with a major theme being to interrogate how the brain protects itself 
[4, 8]. 
 
To summarize, considering the multifactorial nature of stroke, in order to be considered as a 
good candidate for a clinical trial, a treatment should exhibit multimodal actions on the 
multiple cell types composing the neurovascular unit. Consequently, an emerging view is that 
we should preferentially seek and test for drug combinations or multi-therapy, or discovering 
molecules able to stimulate multiple protective and regenerative mechanisms to fight stroke 
[9, 10]. A pertinent experimental approach to identify such candidates came from our 
experience on brain preconditioning through the study of how the brain protects itself against 
ischemia and others stress stimuli. 
 
2. The study of the brain preconditioning opens new rational against stroke 
 
The idea of developing a treatment against stroke inspired by this endogenous protective 
process is appealing. Preconditioning depends on the stimulation of protection and 
regeneration against stroke through direct and/or indirect mechanisms, involving multiple cell 
types, rather than through inhibition of single deleterious events, or targets of most of the 
conventional neuroprotective approaches. Indeed, brain preconditioning refers to a sublethal 
toxic stimulus eliciting an endogenous response, which renders the brain remarkably tolerant 
to a subsequent, normally lethal stimulus of the same insult. Since its original description in 
the brain [11], the discovery that non-ischemic preconditioners (Figure 1) including various 
sublethal insults like epilepsy, endotoxins, anoxia, hyperthermia and spreading depression 
also promote tolerance to ischemia - a phenomenon known as “cross-tolerance” [8, 12, 13] - 
definitely established that the protective response to brain preconditioners is pleiotropic in 
nature. A major conceptual roadblock for clinical translation - the requirement of bringing 
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neurons to the „brink of death‟ during the sublethal preconditioning challenge [14] - can be 
circumvented based on the demonstration that brain preconditioning may be 
pharmacologically/chemically induced by drugs like adenosine or KATP channel agonists [15]. 
Finally, the recent discovery that nutrients like polyunsaturated fatty acids and 
lysophospholipids that form part of our daily diet may be efficient brain preconditionners 
against stroke [16, 17] gave birth to the novel concept of brain preconditioning based on 
nutraceuticals against stroke [18]. 
 
3. The novel concept of brain preconditioning by nutraceuticals against stroke stresses 
that nutritional importance may go beyond stroke prevention  
 
The rationale of supplementation with a non-ischemic preconditioner that could be a natural 
product - a nutrient defined as a nutraceutical - is based on the experimental demonstration 
that certain nutraceuticals can act as “natural preconditioners” to increase brain resistance 
against stroke [18]. Such an approach circumvents issues such as the administration routes 
and timing issues which thus far have plagued the preconditioning and neuroprotectant fields; 
such an approach may be more amenable for translation to the clinical arena, since nutrition 
plays a key role for health and stroke risk in particular. Indeed, most modifiable risk factors of 
stroke - including hypertension, diabetes, hypercholesterolemia, tobacco use, increased 
inflammatory markers, dyslipidemia and obesity - often coexist with improper life-style and 
nutrition, causing imbalances in essential vitamins and nutriments. Striking examples are 
over-consumption of salt, fatty acids that promotes hypertension and diabetes/obesity that 
drastically increase the possibility of having a stroke. In contrast, epidemiologic studies 
usually do not clearly identify a risk factor arising from a deficiency in an essential nutrient in 
the diet. Nevertheless, an important exception is that many clinical and epidemiologic studies 
have shown that insufficient dietary intake of fruits and vegetables or of foods containing 
omega-3 polyunsaturated fatty acids (PUFAs), in the form of Alpha-Linolenic Acid (ALA) 
and the Long Chain derivatives (LC-n-3), Eicosa-Pentaenoic-Acid (EPA) and Docosa-
Hexaenoic-Acid (DHA), represent a risk factor for cardiovascular and cerebral diseases, 
including coronary heart disease and stroke. In addition, several studies investigating the 
importance of dietary omega-3 PUFAs, achieved by consumption of seafood (rich in LC-n-3: 
EPA and DHA) and/or vegetable oils rich in precursor (ALA), proposed omega-3 PUFAs as 
key support for neurons and brain resistance (for review, see [18, 19]. Therefore, nutritional 
products with health benefits or supplemented with such protective nutrients seem promising 
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for reducing the incidence of stroke, encouraging the discovery or characterization of an 
efficient nutraceutical targeted against stroke.  
 
Unfortunately, no such entity like the STAIR recommendations or any other guidelines exist 
to directly address nutraceutical discovery, especially in the field of stroke. Nutraceutical is a 
termed coined from nutrition and pharmaceutical without any regulatory definition, and refers 
to foods or one of its constituents that provides medical or health benefits, including the 
prevention and/or treatment of a disease [20]. Such an open definition may explain, in part, 
why the term is often abused for marketing purposes, and several limitations exist in proving 
the efficiency of a potential candidate to be termed nutraceutical. 
 
The main distinction between nutraceutical and dietary supplements aimed at supporting the 
body with the required amount of a certain nutrient needed for its proper functioning, is that a 
nutraceutical should have a proven efficiency against disease [20]. Thus, a supplement may 
be a nutraceutical;, such overlap increases the risk of confusion, especially if the essential 
distinction of the role of the nutraceutical in combating disease is not well framed. To avoid 
repeating past mistakes in the field, the best chance for success may be to move forward with 
a nutraceutical being able to follow, at least for part, the STAIR recommendations. This goal 
would be achievable by restricting the definition of the term nutraceutical to compounds 
isolated or purified from foods, and demonstrating that efficiency could be evaluated and used 
in medicinal forms. In this framework, the following part of the review argues that Alpha-
Linolenic Acid conforms to this optimal definition of nutraceutical, by identifying its 
relevance in protecting from stroke consequence. 
 
4. Omega-3 supplementation to lower stroke risk: origin of the concept 
 
A body of evidence shows that omega-3 intake in the adult population of developed countries 
is far below the recommended Dietary Reference Intake. This deficiency was associated with 
an increased risk of stroke occurrence and conversely, diets enriched in omega-3, especially 
through the consumption of fatty fish twice a week, lower the risk of having a stroke [21, 22]. 
The first clinical trials examining the effect of fish oil EPA-DHA supplementation on 
cardiovascular death were promising, indicating that omega-3 supplementation may be used 
for lowering stroke risk [23, 24]. That conclusion is disputed by results from recent 
randomized clinical trials examining the effects of fish oil supplementation on cardiovascular 
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disease morbidity and mortality in secondary prevention settings [25, 26]. Nonetheless, 
continued interest in LC-omega-3 was acknowledged by the American Heart Association and 
French recommendations, pointing out the necessity to enrich our daily diet in omega-3 fatty 
acids [27-30].  
 
Additionally, the few preclinical studies, which have examined the effects of fish oil 
supplementation in rodent models of ischemic brain injury, suggested a protective action 
against neuronal damage (for review, see [18, 19, 31]). It is important to note that beneficial 
effects of LC-omega-3 enriched diets were mainly observed when comparing with diets 
lacking EPA/DHA. This may explain in part the inconsistency of recent results of clinical 
trials investigating the effect of omega-3 supplementation: the protection obtained with 
supplementation with LC-omega-3 may only appear in the case of a severe deficiency in the 
patient diet. This reinforces the necessity for a clear distinction between nutraceuticals and 
supplements that should exert a beneficial role compensating a deficiency of the intake. In the 
context of investigating omega-3 as a nutraceutical, protection of the patients by the enriched 
diet should also be obtained when comparing to patients fed a diet already containing omega-
3 fatty acids of the same nature. Such nutraceutical effect of ALA was discretely suggested in 
the “Lyon Diet Heart Study”, which reported a reduced rate of recurrence of myocardial 
infarction, other cardiac events and overall mortality of patients fed an ALA-rich diet as 
compared to those fed the usual post-infarct diet, known as the “prudent diet” that also 
contains ALA and other omega-3 fatty acids [32].  
 
5. Alpha-linolenic acid: from supplements to nutraceuticals for stroke? 
 
5.1. Long underestimated, ALA interest as supplement is now re-evaluated 
 
Indeed, while numerous studies have investigated the beneficial effect of a DHA/EPA-
enriched diet, as well as providing characterization of biophysical and functional properties of 
the nutrient itself, interest in ALA is extremely recent. Several reasons for this early 
disinterest can be surmised. The first reason was conceptual: DHA is a major constituent of 
the brain plasma membranes but ALA is not even incorporated at the brain membrane level. 
In addition, its consumption may not fulfill DHA requirements [33], because of its extremely 
low efficiency of conversion to DHA [34, 35]. This dogma is now disputed because, as 
reviewed by Barcelo-Coblijn, when consumed in adequate amounts over time, ALA exerts 
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identical effects as DHA in several physiological processes [33]. The second reason resulted 
from the simplification in approaches, which considered stroke like any other cardiovascular 
diseases (CVD incidence is lower for an EPA and DHA combination compared to ALA [36, 
37]). Consequently to the recent controversy on the effect of supplementation performed with 
EPA or DHA on stroke and CVD and to the growing evidence of the beneficial effect of 
dietary ALA to protect against CVD, dietary supplementation with ALA regained interest. 
 
A recent body of evidence demonstrates that ALA intake is associated with a reduced risk of 
stroke in humans. It is worth noting that this effect on stroke was not correlated with a 
positive effect on coronary heart disease [38]. A reduced risk of stroke was associated with 
high serum levels of ALA [39]. A lower prevalence of a carotid plaque and inflammation, key 
steps of atherosclerosis considered as one of the major risk factors of stroke, are associated 
with elevated intake of ALA [40-42]. The interest in ALA as a supplement is also reinforced 
by the fact that human do not possess the enzymes for de novo synthesis of ALA, in contrast 
to EPA/DHA; and by the absolute and relative recent changes of omega-6/omega-3 ratio that 
seems mainly mediated by an increase in LA and a decrease in ALA content in the western 
diet [43] 
 
5.2. ALA as a nutraceutical for stroke: proof of concept 
 
Just as for the beneficial effects of an LC-omega-3 enriched diet (observed when comparing 
with diets deficient in EPA/DHA), a diet rich in ALA from perilla oil increases lifetimes of 
hypertensive stroke-prone rats compared to a diet rich in LA from sunflower oil [44]. To 
avoid any confusion between the concept of a supplement and a nutraceutical, we investigated 
whether an ALA enriched diet from rapeseed oil, a rich source of ALA and the only source of 
lipids, could reduce brain damage in a mouse model of ischemic stroke (Figure 2), performed 
by transient occlusion of the middle cerebral artery (MCAO), compared to regular chows 
supplemented in ALA, EPA and DHA in proportions matching the “murine” recommended 
intake [45, 46]. In addition, the ALA enriched diet did not contain any LC-omega-3 EPA or 
DHA. In this paradigm of a 6-week diet enriched in ALA by a factor of three compared to 
regular chows, a reduced mortality rate and smaller infarct size were observed 24 h after 
60min of MCAO [47]. The reduction of the infarct volume was similar or better than those 
observed with high dietary levels of LNC omega-3 provided over the same period of feeding 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Page 10 of 21 
[48]. Since ALA bioconversion to DHA was negligible over the period of investigation, this 
neuroprotection may be attributed to a potential nutraceutical effect of ALA. 
 
5.3. ALA evaluated and used in medicinal forms in rodent model of ischemic stroke 
 
As reviewed above, the main distinction between nutraceuticals and dietary supplements is 
that the proven efficiency on disease was observed - at least - in a mice model of stroke. Thus, 
the additional step was to investigate the hypothesis that the use of ALA could conform to this 
restricted definition of a nutraceutical, where efficiency could be evaluated when used in 
medicinal treatment. Evidence has accumulated that bolus injections of ALA and, to a lesser 
extent, EPA/DHA, is neuroprotective against glutamate-mediated excitotoxicity, a major 
cause of the initial substantial neuronal damage in animal models of neurodegenerative 
conditions and neurological injury, like epileptic seizures [49, 50], acute spinal cord injury 
[31, 51, 52] and focal and global ischemia [17, 50, 52-57]. 
 
With regard to acute neuroprotection, pretreatment and “rapid preconditioning” when 
targeting glutamate excitotoxicity share the same temporal constraint that undermines clinical 
translation. Nevertheless, testing ALA in such a paradigm provided the first indication of its 
nutraceutical capacity as a neuroprotectant. The injection of ALA (i.c.v., 10µM/5µl or i.v., 
500 nmol/kg) preserved 80% of the CA1 hippocampal pyramidal neurons in an in vivo 
transient model of global ischemia, a model for which neuronal death is mainly driven by 
glutamate excitotoxicity, as compared to the 15% survival observed 7 days after 20 min of the 
4-vessel occlusion [50]. In the MCAO model (Figure 2), intravenous injection of ALA 
reduced the infarct volume when injected before, but also up to 6 hours after stroke onset, 
corresponding with post-treatment or postconditioning paradigms [56, 58]. In such a context 
of standardized evaluation of a neuroprotectant candidate, ALA performed like riluzole, a 
drug currently in clinical use for amyotrophic lateral sclerosis in a time-frame of intervention 
compatible within a clinical setting. 
 
When considering nutraceuticals, an interesting aspect offered by the preconditioning and 
postconditioning approaches is that repetitive activation of these endogenous mechanisms 
may lead to sustained protection against ischemic stroke [59, 60]. Such an approach with 
repeated intravenous injections achieved a 3-fold improvement of the long-term survival post-
ischemia, while no improvement was observed with a single ALA injection - described to 
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reduce post-stroke infarct [56, 58]. The surprising number of neuronal death models and 
windows of intervention in which beneficial effects of ALA have been described imply 
multiple temporal and mechanistic benefits. 
 
5.4. The multiple temporal and mechanistic protective effects of ALA 
 
The original mechanistic finding was that ALA can act directly on the neurons by protecting 
them in vitro of neuronal death triggered by excitotoxicity driven by exposure to a Mg
2+-
depleted glycine-supplemented medium (−Mg/+gly) or the addition of an excitotoxic 
concentration of glutamate [50, 58]. The second was that ALA also acts on another cell type 
comprising the neurovascular unit, namely the endothelial cells. Indeed, neuroprotective 
doses of ALA display vasoactive properties. Ex vivo, ALA increased the diameter of the 
basilar but not carotid artery in mice and rats [53], leading to an approximately 30% increase 
in artery diameter, which could account for an increase of the CBF observed in vivo within 30 
min after injection of a neuroprotective dose of ALA [53]. The third mechanistic finding was 
the ability of ALA to stimulate neuronal plasticity. The reduced long-term mortality rate 
observed with repeated ALA injections spaced over several days implied additional protective 
mechanisms other than solely reducing glutamate excitotoxicity within the acute phase of 
stroke. We have directly investigated whether ALA may stimulate spontaneous biological 
functions that are implicated in stroke recovery and targeted by restorative therapies. 
Subchronic ALA treatment induces neurogenesis in the dentate gyrus, identified by an 
increased number of proliferating immature neurons 3 days after the final ALA injection[58]. 
Those immature neurons became mature by 21 days. The concept that ALA improved 
neuronal plasticity was strengthened by the discovery that synaptogenesis was concomitantly 
stimulated by the ALA treatment, as shown by up-regulation of key proteins involved in 
synaptic function (synaptophysin-1, VAMP-2, and SNAP-25) as well as proteins supporting 
glutamatergic neurotransmission (V-GLUT1 and V-GLUT2). In many studies, stimulation of 
neurogenesis and synaptogenesis implied an up-regulation of neurotrophic factors such as 
Brain Derived Neurotrophic Factor (BDNF), for which beneficial effects on stroke have been 
widely described [61]. These changes also correlated with an increase in BDNF protein 
levels, both in vivo, following sub-chronic ALA treatment. Similar results were observed in 
vitro when applying ALA on neural stem cells and hippocampal cultures [58]. With regard to 
stroke management, the protective actions identified with ALA conform with its role as a 
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treatment for stroke, taking in consideration the necessity of a multimodal action mode on the 
neurovascular unit by stimulating multiple protective and regenerative mechanisms. A final 
major mechanistic finding that explains the new concept of nutraceutical being a natural brain 
preconditioner is the demonstration that ALA is a “natural” preconditioner able to induce 
delayed cerebral tolerance to ischemia. 
 
5.5. ALA a nutraceutical stimulating brain preconditioning mechanisms 
 
The capacity of ALA as a non-ischemic preconditioner able to induce brain tolerance against 
excitotoxicity-driven neuronal death was demonstrated in rat models of global ischemia and 
kainic acid-induced epileptic seizures [17]. ALA preconditioning was also successfully 
demonstrated in a mouse model of transient focal ischemia [58]. The temporal window of 
brain protection and the protective pathways triggered by ALA preconditioning paralleled 
preconditioning by sublethal insults and by adenosine and KATP channel agonists that are 
acknowledged as gold standards in chemical preconditionings [15, 17, 54]. ALA 
preconditioning induced the neuroprotective HSP70 heat shock protein and the 
expression/activation of the transcription factor nuclear factor-kB (NFkB) within a similar 
time frame and neuronal localization shared by ischemic, epileptic and chemical 
preconditionings [15, 17, 54]. Such similarities clearly establish ALA as a nutraceutical in its 
capacity to trigger the ubiquitous pleiotropic protective mechanisms of brain preconditioning. 
 
6. Conclusion 
 
This review presents the capacity of alpha-linolenic acid, the precursor of the LC-
omega-3 polyunsaturated fatty acid, for protecting the brain from stroke. This review 
highlights its interest as a supplement to reduce the incidence of stroke and as a nutraceutical 
to increase brain resistance against stroke damage, in both nutritional and medicinal forms. 
The concept underlying the nutraceutical potential of ALA is its pleiotropic targeting of many 
brain cell types, leading not only to inhibition of the deleterious pathways driven by glutamate 
excitotoxicity but also to enhance restorative mechanisms such as neurotrophic factor 
production, neurogenesis and synaptogenesis. The examples of multiple actions of ALA 
illustrate the current importance of reaching a consensus definition of nutraceutical required 
for shaping future research in the field. This point seems mandatory because the 
characterization and use of a nutraceutical like ALA represents a paradigm shift, from 
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focusing solely on the discovery of new drugs designed for clinical neuroprotection, to the 
identification of therapeutic capacity of natural food constituents. This is of importance 
because 1) the medicinal forms of a nutraceuticals may be of advantage as compared to drugs 
or non-natural preconditioners that display ceiling effects (dose/duration) due to their toxic 
side effects; 2) development of nutraceuticals against stroke may largely depend not only 
upon its successful translation to the clinical arena, but also to daily life, notably through 
functional food development. Such a goal opens an interesting avenue - supported by the 
characteristics of ALA as a preconditioner - that may be achieved by integrating knowledge 
drawn from preconditioning research. Though extremely relevant for stroke, this novel 
concept of nutraceutical preconditioning may not be restricted to ALA or stroke, but may in 
fact be extend to other existing or novel nutraceuticals and neuropathologies and 
neurovascular diseases. Hence, the overall effect of ALA, including its capacity to trigger 
preconditioning, appears to be useful for shaping new recommendations in the nutritional as 
well as therapeutic approach of stroke, thereby justifying continued investigation in other 
traumas, epilepsy, SCI and neurodegenerative insults that have been shown to be protected by 
pre- and post-conditioning. 
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9. Legend of the figures 
 
Figure 1: The different natures of brain preconditioners and their perspectives against 
stroke 
Originally, brain preconditioning refers to an endogenous response to a sublethal stimulus in 
the brain, which develops tolerance to a subsequent, normally lethal stimulus of the same 
insult. The protective response to brain preconditioners is pleiotropic in nature. Non-ischemic 
preconditioners include various sublethal insults, pharmacological/chemical agents and 
natural compounds including nutrients that are part of our daily diet. The diet aspect provides 
the rationale of supplementation with a non-ischemic preconditioner that could be a natural 
product - a nutrient defined as a nutraceutical. 
 
Figure 2: Alpha-Linolenic Acid (ALA) as nutraceutical for stroke: proof of concept  
The main distinction between nutraceutical and dietary supplements aimed at supporting the 
body with the required amount of a certain nutrient required for proper function is that a 
nutraceutical should have demonstrated a proven efficiency against disease. Alpha-linolenic 
acid fulfills the restricted definition of the term nutraceutical to compounds isolated or 
purified from foods, and that efficiency could be evaluated, thereby potentially being 
prescribed in medicinal forms. 
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A nutritional approach with an ALA enriched diet from rapeseed oil (left panel) and a 
medicinal approach with intravenous injection of ALA (right panel) reduce brain damage in a 
mouse model of ischemic stroke. 
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